Article
Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
The Prostate - 1 Oct 2002
Cozzi Paul J, Burke Peter B, Bhargav Amit, Heston Warren D W, Huryk Bob, Scardino Peter T, Fong Yuman
Abstract excerpt
BACKGROUND: Attenuated, replication-competent herpes simplex virus mutants offer an exciting new modality in cancer therapy through their ability to selectively replicate within and kill malignant cells with minimal harm to normal tissues. METHODS: This study investigates the efficacy of two such viruses, G207 and NV1020, in human prostatic carcinoma. In vitro studies were performed on four human prostatic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.